Advertisement
Table 2 The inter-relationship between clinico-pathological characteristics and lymphovascular invasion (LBVI H & E ) in patients with primary operable invasive ductal breast cancer
| All patients (n = 360) | LBVIH&E-ve | LBVIH&E+ ve | ( P-value) |
|---|---|---|---|
| n = 258(72%) | n = 102(28%) | ||
| Age (≤50/ >50 years) | 86/175 | 39/63 | 0.379 |
| Size (≤20/ 21-50/ >50 mm) | 147/106/5 | 38/56/8 | <0.001 |
| Grade (I / II / III) | 38/95/125 | 10/29/63 | 0.028 |
| Involved lymph node (-ve/+ve) | 165/93 | 41/61 | <0.001 |
| ER status (no/yes) | 119/139 | 52/50 | 0.406 |
| PR status (no/yes) | 137/121 | 57/45 | 0.634 |
| HER2 status (no/yes) | 211/47 | 78/24 | 0.254 |
| Tumour recurrence (no/local/distant/both) | 213/7/36/2 | 58/10/31/3 | <0.001 |
| Endocrine therapy (no/yes) | 191/63 | 81/18 | 0.184 |
| Chemotherapy (no/yes) | 158/96 | 51/48 | 0.067 |
| Alive/cancer death/non cancer death | 148/54/56 | 41/43/18 | 0.158 |
| Cancer specific survival (months)a | 178(171–188) | 138(121–155) | <0.001 |
| Node-negative patients (n = 206) | n = 165(80%) | n = 41(20%) | |
| Age (≤50/ >50 years) | 51/114 | 16/25 | 0.322 |
| Size (≤20/ 21-50/ >50 mm) | 103/60/2 | 17/22/2 | 0.008 |
| Grade (I / II / III) | 29/60/76 | 5/13/23 | 0.233 |
| ER status (no/yes) | 40/53 | 32/29 | 0.252 |
| PR status (no/yes) | 47/46 | 34/27 | 0.529 |
| HER2 status (no/yes) | 138/27 | 30/11 | 0.123 |
| Endocrine therapy (no/yes) | 118/46 | 31/9 | 0.479 |
| Chemotherapy (no/yes) | 113/51 | 29/11 | 0.658 |
| Tumour recurrence (no/local/distant/both) | 143/6/15/1 | 27/2/10/2 | 0.001 |
| Alive/cancer death/non cancer death | 104/23/38 | 20/12/79 | 0.365 |
| Cancer specific survival (months)a | 190(181–199) | 168(146–190) | 0.010 |
| Triple-negative patients (n = 120) | n = 85(71%) | n = 35(29%) | |
| Age (≤50/ >50 years) | 31/54 | 19/16 | 0.073 |
| Size (≤20/ 21-50/ >50 mm) | 49/34/2 | 14/17/6 | 0.025 |
| Grade (I / II / III) | 1/14/70 | 0/7/28 | 0.888 |
| Involved lymph node (-ve/+ve) | 56/29 | 14/21 | 0.009 |
| Tumour recurrence (no/local/distant) | 69/1/15 | 19/2/14 | 0.004 |
| Endocrine therapy (no/yes) | 76/8 | 31/4 | 0.754 |
| Chemotherapy (no/yes) | 36/48 | 15/20 | 0.999 |
| Alive/cancer death/non cancer death | 50/20/15 | 16/17/2 | 0.936 |
| Cancer specific survival (months)a | 171(155–187) | 123(96–150) | 0.011 |
